• Mira Smart Conferencing
  • Home
  • Table of Contents
  • Advanced Search
 
Advanced Search

Browse All

Current Filters

CLEAR FILTER x

TITLE

Topic:

  • MS and Inflammatory Disease

Filter

Partial Search: Partial searches may be entered manually by pressing enter in the filter input field.
Author Filter: Selecting one or more Authors from the Author drop down list will filter results by Author last name(s) only.

Displaying 116 - 120 of 274

  • Page:
  • 22
  • 23
  • 24
  • 25
  • 26

Effects of ocrelizumab on NK cell activation in Relapsing Multiple Sclerosis

Author:Abbadessa, Gianmarco   Bruzzaniti, Sara   Miele, Giuseppina   Piemonte, Erica   Lepore, Maria Teresa   Signoriello, Elisabetta   Lus, Giacomo   Matarese, Giuseppe   Galgani, Mario   Bonavita, Simona   

Session Name:P6: MS Clinical Trials  

Topic:MS and Inflammatory Disease  

Program Number:P3.004  

Author Institution:University of Campania Luigi Vanvitelli, Naples, Italy  University of Naples Federico II, Naples, Italy  University of Campania Luigi Vanvitelli, NA - Napoli, Italy  

  • View Abstract
  • View Disclosure

Effects of Ozanimod on Cognitive Processing Speed: Findings From the Phase 3 SUNBEAM and DAYBREAK Extension Trials

Author:DeLuca, John   Cohen, Jeffrey A.   Cree, Bruce A. C.   Cheng, Chun-Yen   Sheffield, James K.   Riolo, Jon V.   Silva, Diego   Comi, Giancarlo   Kappos, Ludwig   

Session Name:P6: MS Clinical Trials  

Topic:MS and Inflammatory Disease  

Program Number:P6.001  

Author Institution:Kessler Foundation, West Orange, New Jersey, and Departments of Physical Medicine and Rehabilitation, and Neurology, Rutgers - New Jersey Medical School, Newark, New Jersey, West Orange, NJ  Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, Ohio, Cleveland, OH  Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California, San Francisco, CA  Bristol Myers Squibb, Princeton, New Jersey, Princeton, NJ  Vita-Salute San Raffaele University, and Casa di Cura del Policlinico, Milan, Italy, Milan, Italy  Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland, Basel, Switzerland  

  • View Abstract
  • View Disclosure

Disease Outcomes With Ublituximab in Participants With Highly Active Disease: Subpopulation Analyses of the Phase 3 ULTIMATE I and II Studies in Participants With Relapsing Multiple Sclerosis

Author:Alvarez, Enrique   Steinman, Lawrence   Hartung, Hans-Peter   Fox, Edward   Qian, Peiqing   Wray, Sibyl   Robertson, Derrick   Mok, Koby   Garner, Christopher A   Cree, Bruce   

Session Name:P6: MS Clinical Trials  

Topic:MS and Inflammatory Disease  

Program Number:P6.002  

Author Institution:University of Colorado, Aurora, CO  Stanford Medicine, Stanford, CA  Heinrich Heine University Medical Faculty Departme, Dusseldorf, Germany  Central Texas Neurology Consultants, Round Rock, TX  Swedish Medical Center, Seattle, WA  Hope Neurology, Knoxville, TN  University of South Florida, Tampa, FL  TG Therapeutics, Seal Beach, CA  TG Therapeutics, New York, NY  UCSF, Multiple Sclerosis Center, San Francisco, CA  

  • View Abstract
  • View Disclosure

Comparison of 2-year Teriflunomide Outcomes between DMT-naive and switch patients with Relapsing MS: subanalysis of the Real-World TERICARE study

Author:Meca Lallana, Jose   Prieto, Jose María   Caminero, Ana Belén   Olascoaga, Javier   Casademont Portell, Rosa   Forner, Mireia   

Session Name:P6: MS Clinical Trials  

Topic:MS and Inflammatory Disease  

Program Number:P6.003  

Author Institution:Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, Murcia, Spain  Complejo Hospitalario Universitario de Santiago de Compostela, Spain, Santiago de Compostela, Spain  Complejo Asistencial de Ávila, Spain, Ávila, Spain  Hospital Universitario Donostia, Spain, Donostia-San Sebastián, Spain  Sanofi, Barcelona, Spain, Barcelona, Spain  

  • View Abstract
  • View Disclosure

Improvement in Cognitive Processing Speed With Ofatumumab in Patients With Relapsing Multiple Sclerosis

Author:Benedict, Ralph   Penner, Iris Katharina   Cutter, Gary   Kappos, Ludwig   Coyle, Patricia   Piani-Meier, Daniela   Azmon, Amin   Boer, Ibolya   Su, Wendy   Cohen, Jeffrey   

Session Name:P6: MS Clinical Trials  

Topic:MS and Inflammatory Disease  

Program Number:P6.005  

Author Institution:Department of Neurology, University At Buffalo, Buffalo, NY  Medical Faculty, Department of Neurology, Heinrich Heine University, COGITO Center for Applied Neurocognition and Neuropsychological Research, Düsseldorf, Germany  UAB School of Public Health, Birmingham, AL  Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland  Department of Neurology, SUNY At Stony Brook, Stony Brook, NY  Novartis Pharma AG, Basel, Switzerland  Novartis Pharmaceuticals Corporation, East Hanover, NJ  Department of Neurology, Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland, OH  

  • View Abstract
  • View Disclosure

Displaying 116 - 120 of 274

  • Page:
  • 22
  • 23
  • 24
  • 25
  • 26

© 2015 Mira Smart Conference | http://www.mirasmart.com